GPCR Screening With Reconstituted Membranes and Engineered G Proteins
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drug discovery campaigns for G protein-coupled receptors (GPCRs) are limited by inefficient cell-based assays, lack of specificity in targeting desired therapeutic pathways, and inability to isolate ligands with predefined pharmacology from complex mixtures, hindering the development of biased agonists.
Innovation Solution
A GPCR assay platform comprising the ADSoRB and TRUPATH systems, which simulate cellular signaling processes by altering receptor conformations and measuring G protein heterotrimer complex dissociation to isolate ligands with defined pharmacology, enabling efficient screening of large and complex libraries for biased agonists.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cell-based assays are used for GPCR screening, then ligand binding can be detected, but the assays are highly amplified, inefficient, and have low fidelity to the actual pathway under study
Solution Approach 1:
The patent extracts the GPCR from the complex cellular environment and reconstitutes it in simplified membrane systems (nanodiscs, liposomes, or detergent micelles). This extraction removes the amplification and noise inherent in whole-cell assays while preserving the receptor's native signaling capabilities, thereby improving measurement precision without sacrificing productivity.
Solution Approach 2:
The patent introduces engineered G proteins with enhanced signaling properties as intermediaries between the GPCR and downstream effectors. These engineered transducers (e.g., Gαq-Chimera, Gβ1γ2-Chimera) provide more faithful and measurable signaling responses, improving the fidelity of pathway representation while enabling high-throughput screening.
2Manufacturing precision
If conventional screening strategies are used, then general ligand binding can be assessed, but they cannot isolate ligands with predefined pharmacology from complex mixtures
Solution Approach 1:
The patent employs multiple specialized assay formats, each optimized for detecting specific pharmacological properties (e.g., biased agonism, allosteric modulation, pathway selectivity). By creating locally optimized detection systems for different pharmacological questions, the patent achieves high precision in ligand characterization without requiring a single overly complex universal system.
Solution Approach 2:
The patent segments the screening process into distinct modular assays: binding assays, functional signaling assays, biased agonism assays, and allosteric modulation assays. Each module addresses a specific pharmacological property, allowing systematic isolation and characterization of ligands with predefined pharmacology from complex mixtures through sequential screening.
3Adaptability or versatility
If good assays exist for only a small fraction of G protein signaling pathways, then those pathways can be studied, but therapeutic intervention is limited to best studied pathways
Solution Approach 1:
The patent develops a universal assay platform based on reconstituted GPCR-membrane systems that can accommodate any G protein-coupled receptor and any G protein family member. The use of standardized membrane environments (nanodiscs, liposomes) and engineered G proteins creates a multi-functional system that maintains high measurement precision across all 16 non-visual G protein signaling pathways, enabling versatile pathway coverage without sacrificing assay quality.
Data Source
AI summary
Disclosed herein is a G protein-coupled receptor (GPCR) assay platform comprised of two complementary systems that equate dynamic intermolecular interactions between a receptor and transducer with more complex stimulus-response cascades in living cells. In the disclosed in vitro ADSoRB method, the forced dissociation of transducers like G protein heterotrimers from receptors alters receptor conformations and ligand interactions to simulate pathway activation in a cell. In the disclosed TRUPATH method, measuring the extent of engineered G protein heterotrimer complex dissociation provides single transducer resolution in a cell.